Passage Bio
NEWS
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
The Series A rounds are the latest in a string of financing announcements made over the past few months.
Passage Bio’s first attempt to develop a GM1 gangliosidosis gene therapy treatment has run into a roadblock in the form of a clinical hold.
Life sciences and pharma companies from across the globe strengthen their leadership teams and board with this week’s Movers & Shakers.
The company offered 12 million shares at $18 per share and raised $216 million, 72% more than originally expected.
Pharma and biotech companies strengthen their leadership teams and boards with this week’s Movers & Shakers.
BioSpace is proud to present its NextGen Bio “Class of 2020,” a list of up-and-coming life science companies in North America that launched no earlier than mid-2018.
Companies strengthen their leadership teams and boards of directors with this week’s slate of Movers & Shakers.
JOBS
IN THE PRESS